# Exploring the Mechanism of Primary Resistance to Third-generation EGFR-TKIs as First-line Treatment in EGFR-positive Advanced NSCLC (PRECISE Study)

> **NCT05598528** · — · RECRUITING · sponsor: **Second Xiangya Hospital of Central South University** · enrollment: 210 (estimated)

## Conditions studied

- Lung Cancer, Non-small Cell
- EGFR Gene Mutation
- EGFR-TKI Resistant Mutation
- Primary Resistance
- Circulating Tumor DNA

## Interventions

- **OTHER:** Genomic profiles detection
- **OTHER:** circulating tumor DNA detection

## Key facts

- **NCT ID:** NCT05598528
- **Lead sponsor:** Second Xiangya Hospital of Central South University
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2021-09-28
- **Primary completion:** 2025-12-31
- **Final completion:** 2026-12-31
- **Target enrollment:** 210 (ESTIMATED)
- **Last updated:** 2024-12-02

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05598528

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05598528, "Exploring the Mechanism of Primary Resistance to Third-generation EGFR-TKIs as First-line Treatment in EGFR-positive Advanced NSCLC (PRECISE Study)". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT05598528. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*